We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HIV regimen

News List

Can new Dovato data jump-start uptake of 2-drug HIV regimen? ViiV hopes so fiercepharma
July 28, 2019
Previous clinical results for ViiV Healthcare’s vaunted two-drug HIV regimens have yet to pose a big threat to chief rival Gilead Sciences. But the GlaxoSmithKline joint venture aims to change that with two new sets of data.
ViiV reaches another milestone in the development of a long-acting HIV regimen pharmaceutical-technology
July 31, 2017
On July 24, 2017, ViiV Healthcare announced positive results from 96-week data obtained from a Phase IIb, open-label study (LATTE-2) investigating the safety and efficacy of a two-drug...
ViiV study shows efficacy of two-drug HIV regimen pharmatimes
February 16, 2017
ViiV Healthcare has unveiled late-stage data showing that an experimental two-drug regimen of its dolutegravir and Janssen Science's rilpivirine was comparable in efficacy to three- or four-drug antiretroviral regimens in virologically suppressed patients